Publication: Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children
Issued Date
2015-06-01
Resource Type
ISSN
14321998
03010449
03010449
Other identifier(s)
2-s2.0-84930083746
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Radiology. Vol.45, No.6 (2015), 831-839
Suggested Citation
Nichanan Ruangwattanapaisarn, Albert Hsiao, Shreyas S. Vasanawala Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatric Radiology. Vol.45, No.6 (2015), 831-839. doi:10.1007/s00247-014-3226-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36421
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children
Other Contributor(s)
Abstract
© 2014, Springer-Verlag Berlin Heidelberg. Background: Ferumoxytol is an ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle agent used to treat iron deficiency anemia in adults with chronic kidney disease. Objective: We aim to determine the feasibility of using ferumoxytol for clinical pediatric cardiac and vascular imaging. Material and methods: We retrospectively identified 23 consecutive children who underwent MRI with ferumoxytol (11 males; mean age: 7.4 years, range: 3 days–18 years), yielding 12 abdominal MR angiography and 15 cardiac MRI studies. Medical records were reviewed for the clinical indication, ferumoxytol dose, injection rate, sedation and any complication. A two-reader consensus scored the images on a five-point scale for overall image quality and delineation of various anatomical structures. Signal-to-background ratios for abdominal aorta and inferior vena cava for abdominal cases and blood pool-myocardium contrast ratios for cardiac cases were calculated. The confidence intervals for obtaining a score of three or above for each image parameter were calculated by using adjusted Wald method. Results: For abdominal MR angiography, average scores for overall image quality, as well as delineation of the hepatic artery, superior mesenteric artery, renal artery and veins were 4.5, 4.3, 4.3, 3.7 and 4.7, respectively. For cardiac exams, the average scores for overall image quality, systemic arteries, pulmonary arteries, pulmonary veins, valves and ventricles were 4.4, 4.6, 4.1, 4.8, 4.1 and 4.7, respectively. For all parameters, the lower bound for the proportion of cases to have a score of 3 or above was 65%. Signal-to-background ratios for aorta and abdominal veins averaged 86 +/− 74 and 86 +/− 77 for full-dose images, and 23 and 18 for half-dose images, respectively. Mean blood pool to myocardium contrast ratio was 3:3. Conclusion: Ferumoxytol can provide excellent image quality for pediatric body MR angiography/MR venography at a dose of 1.5 or 3 mg Fe/kg. Further investigation should be directed toward understanding the lowest dose that can be administered.